Jerusalem, 18 November, 2025 (TPS-IL) — Israeli biopharmaceutical company BioLineRx Ltd. has received U.S. patent approval for GLIX1, a therapy targeting cancers where cytidine deaminase (CDA) is not over-expressed—covering more than 90% of cancers. The patent protects GLIX1 until 2040, with a possible five-year extension.
Originally developed for glioblastoma, GLIX1 will enter first-in-human trials in early 2026, with pre-clinical studies ongoing for other cancer types.